Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Surufatinib with Chemoradiotherapy in Stage III NSCLC
NCT07609121Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Jun 2026; status: recruiting.
02
Drugs
surufatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07609121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609121.